Piper Sandler launched the coverage of a raft of cancer-focused biotechs with bullish views on Monday while issuing a Neutral recommendation on Summit Therapeutics (NASDAQ:SMMT), citing an unfavorable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results